Motor and Non-Motor Features of Parkinson's Disease – A Review of Clinical and Experimental Studies

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 4, 2012-06 ,pp. : 439-449

Bentham Science Publishers

Access to resources Recommend Favorite

Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation

By Chan Phylinda   Nutt John   Holford Nicholas  

Pharmaceutical Research, Vol. 24, Iss. 4, 2007-04 ,pp. : 791-802

Springer Publishing Company

Access to resources Recommend Favorite

Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?

By  

Current Medicinal Chemistry, Vol. 25, Iss. 31, 2018-09 ,pp. : 3682-3702

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 8, 2013-12 ,pp. : 1128-1142

Bentham Science Publishers

Access to resources Recommend Favorite

Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease

By Solís-García del Pozo Julián   Mínguez-Mínguez Sara  

Expert Opinion on Drug Safety, Vol. 12, Iss. 4, 2013-07 ,pp. : 479-486

Informa Healthcare

Access to resources Recommend Favorite